Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients -- Data Supplement

Posted as supplied by author

Table A Individual results of unconfounded trials of one antiplatelet regimen versus control

Trial name	Ref	Data	Treatment regimen	Average duration	Patients		Non-fatal MI		Non-fatal stroke		Vasc deaths		Vasc events		Non vasc deaths		Major bleeds
Trial name	Ref	Data	Treatment regimen	Average duration	APT	Ctrl	APT	Ctrl	APT	Ctrl	APT	Ctrl	APT	Ctrl	APT	Ctrl	APT		Ctrl
Previous myocardial infarction
Cardiff-I	1	I	A300	13m	615	624	10	15	-	-	47	61	57	76	2	4	-	(0)	-	(0)
Cardiff-II	2	I	A900	12m	847	878	31	65	0	0	98	122	129	187	5	5	-	(0)	-	(0)
PARIS-I	3	I	A972 + D225	41m	1620	406x4	105	34	15	3	147	45	265	82	26	7	-	(0)	-	(0)
PARIS-II	4	I	A990 + D225	23m	1563	1565	64	104	18	30	98	105	179	235	13	9	-	(0)	-	(0)
AMIS	5	I	A1000	38m	2267	2257	140	173	29	49	214	199	379	411	32	20	-	(0)	-	(0)
CDP-A	6	I	A972	22m	758	771	27	32	7	9	43	61	76	102	2	4	-	(0)	-	(0)
GAMIS	7	I	A1500	24m	317	309	11	15	0	0	22	30	33	45	5	2	-	(0)	-	(0)
ART	8	I	S	20m	813	816	33	38	4	10	65	82	102	130	9	7	-	(0)	-	(0)
ARIS	9	I	S	30m	365	362	14	26	1	4	25	25	40	55	4	2	0	(0)	0	(0)
Micristin	10	T	A1500	24m	672	668	22	35	9	15	34	56	65	106	15	15	2	(1)	2	(1)
Rome	11	T	D150	72m	40	40	5	7	-	-	4	12	9	19	0	0	-	(0)	-	(0)
White	12	P	A50 + D400	12m	107	108	9	8	-	-	2	6	11	14	2	0	-	(-)	-	(-)
Acute myocardial infarction
Gent-AMI	13	T	D400	28d	60	60	2	4	1	0	8	3	11	7	1	0	-	(0)	-	(0)
ISIS-pilot	14	I	A325 (SK), A325, A325 (H), A325 (H + SK)	1m	313	306	7	9	1	2	25	35	33	46	0	0	1	(0)	1	(0)
ISIS-2	15	I	A162.5 (SK), A162.5	35d	8587	8600	74	161	29	52	815	1026	915	1236	2	7	24	(2)	18	(3)
French	16	T	F	6m	234	230	7	23	-	-	2	3	9	26	0	0	1	(0)	1	(0)
Dutch-sulphinpyrazone	17	T	S (W)	21d	50	50	0	0	0	0	2	4	2	4	0	0	0	(0)	0	(0)
Dutch-aspirin	18	I	A100 (H)	3m	50	50	2	6	1	0	9	12	12	18	0	0	0	(0)	0	(0)
Huddinge	19	T	A167	30d (12m)	10	10	0	0	0	0	0	0	0	0	0	1	0	(0)	0	(0)
Jones	20	T	DZ	1m	60	60	-	-	-	-	10	11	10	11	0	0	-	(0)	-	(1)
Knudsen-A	21	T	TC500	3m	24	19	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
Johannessen	22	T	A150 + D225	14d	11	9	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
Wilcox	23	P	S	10d	49	49	-	-	-	-	5	1	5	1	0	0	-	(0)	-	(0)
GRAND	24	T	GRB	1m	63	64	0	2	0	0	3	5	3	7	0	0	0	(0)	0	(0)
Frankfurt	25	T	A1320 + D300, A1320	14d	25	14x2	0	0	0	0	1	1	1	1	0	0	0	(0)	0	(0)
Louvain-sulphinpyrazone	26	P	S	7d	15	14	-	-	-	-	2	0	2	0	0	0	-	(-)	-	(-)
APRICOT	27	I	A325 (H + FIB)	3m	107	95	3	10	0	0	1	2	4	12	0	0	-	(-)	-	(-)
Previous stroke or transient ischaemic attack
AITIA	28,29	I	A1200	17m	162	157	4	2	12	20	10	13	26	35	0	3	3	(0)	0	(0)
Reuther	30	I	A1500	24m	30	30	0	0	2	2	0	3	2	5	0	0	0	(0)	1	(0)
Canadian Co-op*	31,32	I	S, A1300 + S, A1300	26m	446	139x3	16	0	58	15	29	15	100	30	12	2	-	(0)	-	(0)
Toulouse-TIA	33	I	A900 + D150, A900	34m	284	156x2	0	2	5	7	18	7	23	16	11	5	-	(0)	-	(0)
AICLA	34	I	A990, A990 + D225	36m	400	204x2	4	9	32	25	25	12	61	46	11	6	0	(0)	0	(0)
Danish Co-op	35	I	A1000	33m	101	102	2	8	14	12	8	8	23	27	3	2	0	(0)	0	(0)
Britton	36	I	A1500	24m	253	252	11	10	22	18	28	29	59	55	6	8	3	(0)	0	(0)
Danish low-dose	37	I	A50	23m	150	151	0	2	8	12	13	7	21	21	1	3	-	(0)	-	(0)
ESPS-1	38	I	A975 + D225	23m	1250	1250	21	35	83	128	79	105	183	263	28	50	-	(0)	-	(0)
UK-TIA	39	I	A300, A1200	50m	1621	814x2	39	32	126	83	180	86	342	193	41	36	9	(2)	0	(0)
Stoke	40	T	D400-800	25m	85	84	-	-	12	11	11	9	23	20	2	0	-	(0)	-	(0)
Memphis	41	T	S	48m	73	75	-	-	10	6	9	16	19	22	0	0	-	(0)	-	(0)
Blakely-stroke	42	I	S	38m	143	147	0	1	3	2	30	39	33	42	16	13	-	(0)	-	(0)
CATS	43	I	TC500	28m	531	541	11	15	67	86	35	43	112	139	31	22	1	(0)	0	(1)
Gent-stroke	44	I	SC	25m	222	225	3	4	23	22	21	31	47	57	16	17	0	(0)	0	(0)
Ross Russell	45	T	TC500	3m	11	11	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
Birmingham-B	46	T	S	4m	50	50	0	0	0	2	1	2	1	4	0	0	1	(0)	0	(0)
Charing Cross	47	T	S	18m	25	30	-	-	5	5	0	2	5	7	0	0	-	(0)	-	(0)
McKenna-III	48	T	TC500	16d	27	26	0	0	2	0	0	2	2	2	0	0	0	(0)	0	(0)
SALT	49	I	A75	32m	676	684	21	32	61	74	58	67	138	169	15	20	3	(0)	1	(0)
ESPS-2	50,51	T	A50 + D400, D400, A50	24m	4953	1649x3	59	22	412	191	360	124	825	332	195	78	45	(13)	10	(2)
Acute stroke
Tokyo	52	T	TC300	3m	15	14	-	-	2	1	0	2	2	3	0	0	0	(0)	0	(0)
Ciuffetti	53	T	TC500	21d	15	15	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
CAST	54	I	A160	28d	10335	10320	-	-	202	216	343	398	545	614	0	0	47	(39)	27	(31)
IST	55	I	A300 (H), A300	14d	9720	9715	-	-	225	304	871	909	1096	1213	0	0	88	(21)	45	(12)
MAST-Italy†	56	I	A300	10d	153	156	0	1	3	1	16	20	19	22	0	0	0	(0)	0	(0)
Toulouse-II	57	T	A990 + D225	10d	40	40	-	-	-	-	7	5	7	5	0	0	-	(0)	-	(0)
Ohtomo-1	58	P	OKY	14d (28d)	140	143	0	0	-	-	1	1	1	1	0	0	0	(0)	1	(0)
Unstable angina
VA-pilot	59	I	A324	3m	26	24	0	1	0	0	1	3	1	4	0	0	0	(0)	0	(0)
VA-main	60	I	A324	3m	661	677	27	49	3	2	15	24	45	75	0	0	0	(0)	0	(0)
Canadian	61	I	A1300 + S	18m	416	139x3	24	7	4	0	28	13	54	20	3	0	1	(0)	0	(0)
RISC	62,63	T	A75	12m	474	471	36	69	0	0	9	16	45	85	2	2	0	(0)	0	(0)
ALDUSA-pilot‡	64	I	A325, A40	12m	56	28x2	5	0	1	0	1	1	7	1	0	0	-	(0)	-	(0)
STAI	65,66	I	TC500	5m	314	338	15	30	0	2	8	16	23	48	0	0	-	(0)	-	(0)
Prandoni	67	I	A50 + D400	12m	44	44	5	11	0	0	1	0	6	11	1	0	-	(0)	-	(0)
Théroux	68	I	A650, A650 (H)	6d (3m)	243	236	6	12	0	0	0	2	6	14	0	0	4	(0)	2	(0)
Florida UA¥	69	I	TC500	14d	12	12	2	2	0	0	0	0	2	2	0	0	0	(0)	0	(0)
ATACS-pilot§	70	T	A80 (H + W)	3m	37	24x2	0	3	-	-	0	1	0	4	0	0	1	(0)	0	(0)
Plaza	71	I	TF 900	6m	143	138	6	17	-	-	2	0	8	17	0	0	0	(0)	0	(0)
Modena	72	T	TR	6m	71	73	1	5	-	-	1	5	2	10	-	-	-	(-)	-	(-)
Coronary artery bypass
McEnany	73	T	A1200	22m	71	77	0	2	0	0	1	3	1	5	0	0	0	(0)	0	(0)
Brooks	74	T	A990 + D225 (W)	12m	160	160	-	-	-	-	8	4	8	4	0	0	3	(1)	1	(0)
Mayo-A	75	T	A975 + D225	12m	202	205	-	-	-	-	5	6	5	6	-	-	0	(0)	1	(0)
Liège-I	76	T	TC500	3m	75	75	0	0	0	1	0	1	0	2	0	0	0	(0)	0	(0)
Liège-II	77	T	TC500	12m	88	87	1	3	0	2	2	1	3	6	0	2	0	(0)	0	(0)
Pantely	78	T	A975 + D225	6m	18	30	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
Wadsworth	79	T	A975 + D225, A975	12m	96	51x2	-	-	1	1	2	1	3	2	0	0	-	(0)	-	(0)
Lorenz	80	T	A100	4m	29	31	0	1	0	1	2	2	2	4	0	0	0	(0)	0	(0)
VA Co-op CABG	81	T	A325, A975, A975 + D225, S801	12m	619	153x4	40	11	5	3	22	2	67	16	4	3	30	(0)	2	(0)
Brussels	82	T	A200 + D400 (H)	12m	24	25	1	2	0	1	1	0	2	3	0	0	-	(0)	-	(0)
GESIC	83	T	A150, A150 + D225	28d	741	371x2	-	-	-	-	22	5	22	5	0	0	16	(0)	5	(0)
Basel	84	T	A50 + D400	9m	62	63	0	1	-	-	0	0	0	1	0	0	0	(0)	0	(0)
Leeds-B	85	T	A990 + D225 (W)	6m	61	64	0	0	0	0	1	1	1	1	0	0	1	(0)	1	(0)
Czech	86	T	A1000 + D225	12m	47	46	0	2	0	0	0	1	0	3	0	0	0	(0)	0	(0)
Thaulow	87	T	A975 + D225	3m	34	35	0	2	0	0	1	1	1	3	0	0	2	(0)	0	(0)
Guiteras	88	T	A150 + D225, D225 + TF900	7m	141	68x2	1	0	0	0	10	3	11	3	0	2	0	(0)	0	(0)
Sydney	89	T	A324	12m	127	110	-	-	-	-	-	-	-	-	-	-	1	(0)	0	(0)
Des Moines	90	T	A20 + D100	12m	60	54	-	-	0	1	0	0	0	1	-	-	-	(-)	-	(-)
Zurich	91	T	TC500 (NC)	3m	50	50	4	7	0	0	0	0	4	7	0	0	12	(0)	2	(0)
Knudsen-B	92	T	TC500	6m	9	10	-	-	-	-	-	-	-	-	-	-	1	(0)	0	(0)
Romeo	93	T	TC500	3m (12m)	20	20	-	-	-	-	0	0	0	0	0	0	-	(0)	-	(0)
Baur**	94	T	S	10d	130	125	8	3	0	0	1	0	9	3	0	0	0	(0)	0	(0)
Kohn	95	P	TC500	14d	21	12x2	-	-	-	-	0	0	0	0	0	0	1	(0)	0	(0)
Toronto-dipyridamole-1	96	T	D400	48h	20	20	1	0	-	-	0	0	1	0	0	0	-	(0)	-	(0)
Hockings	97	T	A100	6m	72	72	2	2	0	0	0	1	2	3	0	0	6	(0)	4	(0)
Ekestrom	98	T	D400	12m	174	186	2	2	2	4	2	2	6	8	0	0	2	(0)	3	(0)
German-sulotroban	99	P	ST	21d	90	85	0	1	1	0	0	1	1	2	0	0	27	(0)	15	(0)
Coronary angioplasty
TACT	100	T	TC500	6m	177	173	5	10	1	1	1	0	7	11	0	0	0	(0)	0	(0)
Toronto	101	T	A990 + D225 (H)	6m	187	189	7	25	0	0	0	0	7	25	0	0	0	(0)	0	(0)
White	102	T	TC500, A650 + D225	6m	245	127x2	14	10	0	1	2	1	16	12	0	0	0	(0)	0	(0)
Finci	103	T	ST	6m	54	53	2	0	0	0	0	1	2	1	0	0	0	(0)	0	(0)
Perth	104	T	A100	6m	124	128	0	2	-	-	-	-	0	2	-	-	-	(-)	-	(-)
Dunedin	105	T	A300 + D225	12m	35	37	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
Mayo-PTCA	106	P	A975 + D225	48h	102	105	3	2	-	-	0	0	3	2	0	0	-	(-)	-	(-)
Oriol	107	T	TF 900	6m	171	171	2	1	0	1	0	0	2	2	0	0	1	(0)	1	(0)
M-HEART II	108	P	A325, ST	6m	497	255x2	5	10	-	-	1	1	6	11	-	-	-	(-)	-	(-)
Stable angina/coronary artery disease
Atlanta	109	T	D150	6m	30	30	3	4	1	0	1	0	5	4	0	0	0	(0)	0	(0)
Becker	110	T	D225	5m	14	13	0	0	0	0	1	0	1	0	0	0	0	(0)	0	(0)
Mayo-B	111	T	A975 + D225	60m	185	185	10	22	0	4	11	12	21	38	0	0	0	(0)	0	(0)
Berglund	112	T	TC500	2m	21	17	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
Wirecki	113	T	D150	7m	28	28	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
SAPAT	114	T	A75	50m	1009	1026	40	61	21	27	53	71	111	159	29	35	18	(9)	11	(5)
VA bypass IV-B	115	P	A325	24m	161	173	3	3	-	-	3	4	6	7	0	0	-	(-)	-	(-)
Heart failure
Barzizza	116	T	A300, A300 + D200	6m	52	27x2	0	0	0	0	1	2	1	2	0	0	0	(0)	0	(0)
Den Ottolander	117	T	A1500 + RA233	21d	14	14	0	0	0	0	3	3	3	3	-	-	0	(0)	0	(0)
Atrial fibrillation
SPAF-I	118	T	A325	15m	552	568	8	8	16	36	25	35	49	79	14	15	6	(2)	8	(4)
AFASAK	119, 120	T	A75	12m	336	336	-	-	10	13	19	19	29	32	5	8	1	(0)	0	(0)
EAFT	121	T	A300	28m	404	378	3	4	45	49	78	78	126	130	24	21	1	(3)	1	(2)
Fornaro	122	T	ID	36m	98	98	1	3	0	1	7	9	8	13	0	0	0	(0)	0	(0)
Cardiac valve disease
Steele-RHD	123	T	S	48m	78	76	0	0	2	10	7	7	9	17	0	1	0	(0)	0	(0)
London	124	P	A75	38d	4	5	0	1	0	2	0	0	0	2	0	0	-	(-)	-	(-)
Thai	125	T	A325	48m	307	308	0	1	5	9	56	41	61	51	6	8	-	(-)	-	(-)
Cardiac valve surgery
Sullivan	126	T	D400 (W)	12m	79	84	2	1	3	9	10	8	15	18	2	2	2	(0)	5	(0)
Altman	127	T	A500 (NC)	24m	65	69	0	0	0	3	2	3	2	6	0	1	4	(0)	3	(0)
Norwegian	128	T	A1000 (W)	24m	75	73	0	1	4	5	2	4	6	10	1	2	0	(0)	0	(0)
PACTE	129, 130	T	D375 (OAC)	12m	183	202	0	1	1	2	10	25	11	28	0	9	0	(0)	1	(1)
Leeds-A	131	I	D225-400 (W)	30m	68	87	0	0	1	7	6	7	7	14	2	0	-	(1)	-	(0)
Starkman	132	T	D375 (OAC)	12m	132	127	-	-	-	-	5	3	5	3	0	0	-	(0)	-	(0)
Canadian valve	133	I	A100 (H + W)	48m	186	184	3	2	7	11	5	17	14	30	4	5	18	(0)	13	(3)
Intermittent claudication
VA Co-operative	134	T	A975 + D225	42m	110	121	10	8	2	7	24	25	36	40	13	12	1	(0)	1	(1)
Hess	135	T	A990, A990 + D225	24m	160	80x2	2	0	0	3	3	0	5	3	2	0	0	(0)	0	(0)
STIMS	136	T	TC500	67m	346	341	45	42	18	19	28	47	91	108	20	19	8	(0)	0	(0)
Aukland	137	T	TC500	12m	33	32	0	1	0	0	1	1	1	2	0	0	0	(0)	0	(0)
ACT	138	T	TC500	6m	83	86	0	0	0	3	0	0	0	3	1	1	0	(0)	0	(0)
US-ticlopidine	139	T	TC500	6m	100	103	0	1	1	1	1	3	2	5	0	0	1	(0)	0	(0)
Stiegler	140	T	TC500	13m	57	57	0	0	0	0	1	1	1	1	1	0	0	(0)	0	(0)
Schoop-I	141, 142, 143	T	A990, A990 + D225	60m	200	100x2	4	3	2	0	8	4	14	7	2	0	3	(0)	0	(0)
Kakkar	144	T	SC	6m	18	22	0	1	0	0	0	0	0	1	0	1	0	(0)	0	(0)
Katsumura	145	T	TC500	42d	93	100	0	0	0	0	0	1	0	1	0	1	0	(0)	0	(0)
Balsano	146	T	TC500	21m	76	75	1	0	0	1	0	1	1	2	1	2	0	(0)	0	(0)
Hurlow	147	T	TC100-500	2m	30	10x3	0	0	0	0	0	1	0	1	0	0	0	(0)	0	(0)
Louvain-I	148	T	SC	2m	15	15	-	-	-	-	0	1	0	1	0	0	-	(-)	-	(-)
Munich-A	149	T	A1500	24m	92	84	2	2	1	0	2	4	5	6	1	0	2	(0)	0	(0)
Munich-B	149	T	A1500	24m	42	40	1	0	0	1	3	1	4	2	1	1	1	(0)	1	(0)
Portsmouth-B	150	T	TC500	6m	17	18	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
Bourde	151, 152	T	TC500-1000	1m	14	12	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
Holm	153	T	SC	9m	20	20	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
Cloarec	154	T	TC500	6m	66	66	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
Signorini	155	T	ID	6m	28	24	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
Krause	156	T	TC500	4m	19	19	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
Louvain-II	157	T	SC	6m	27	24	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
ADEP	158	I	PI	18m	1150	1154	17	19	10	11	6	11	33	41	14	11	-	(-)	-	(-)
EMATAP	159	T	TC500	6m	304	311	0	3	2	4	4	5	6	12	3	1	0	(0)	0	(0)
Neirotti	160	T	PI	18m	10	10	0	1	0	0	0	0	0	1	-	-	-	(-)	-	(-)
Nottingham	161	P	ST (H + SK)	48h (30d)	13	8	-	-	-	-	2	0	2	0	0	0	-	(-)	-	(-)
Peripheral grafts
Rochester	162	T	A975, A975 + D225	12m	32	17x2	0	0	1	0	2	0	3	0	0	0	1	(0)	0	(0)
McCollum	163	T	A600 + D300	34m	286	263	14	6	14	16	25	39	53	61	15	7	3	(1)	3	(0)
Kester	164	T	A990 + D225	12m	33	32	0	0	0	0	4	0	4	0	0	0	0	(0)	0	(0)
Kohler	165	T	A975 + D225	24m	50	50	-	-	-	-	2	2	2	2	2	0	-	(0)	-	(0)
Loew bypass	166	T	A1500	12m	215	213	0	0	0	0	0	0	0	0	0	0	1	(0)	2	(0)
Schettler	167	T	S	6m	33	30	0	1	0	0	2	0	2	1	0	0	-	(0)	-	(0)
Blakely-PVD	168	T	S	36m	75	90	0	0	0	1	1	2	1	3	0	0	-	(0)	-	(0)
Basellini	169	T	TC500	6m	25	25	0	0	0	0	0	0	0	0	1	0	0	(0)	1	(0)
Goldman	170	T	A900 + D225	12m	22	31	-	-	-	-	0	2	0	2	0	0	-	(0)	-	(0)
Zekert-IV	171	T	A1500	14d	148	150	0	0	0	0	1	3	1	3	3	2	0	(1)	1	(1)
Harjola	172	T	A1500 + D450, D450, A1500	10d	300	100x3	0	0	0	1	0	2	0	3	0	0	0	(0)	0	(0)
Nevelsteen	173	T	TC500	12d	30	30	-	-	1	0	-	-	1	0	-	-	-	(-)	-	(-)
Peripheral angioplasty
Heiss	174	T	A990 + D225, A300 + D225	6m	132	67x2	3	2	1	1	1	1	5	4	0	0	0	(0)	0	(0)
Bern/Zurich	175	T	SC (OAC)	12m	62	61	-	-	0	0	0	0	0	0	2	2	1	(0)	0	(0)
BMFT-II	176	T	A990 + D225	36m	170	164	1	3	-	-	4	4	5	7	4	0	1	(0)	2	(0)
Bergqvist	177	P	A50 + D400	30d	108	115	-	-	-	-	2	2	2	2	-	-	-	(-)	-	(-)
Haemodialysis
Pineo	178	T	S	6m	30	32	-	-	-	-	1	3	1	3	0	0	2	(0)	1	(0)
Majerus	179	T	A160	5m	19	25	-	-	-	-	1	1	1	1	0	0	0	(0)	0	(0)
Andrassy	180	T	A1000	28d	47	45	0	0	0	0	0	0	0	0	0	0	2	(0)	2	(0)
Japanese-A	181	T	TC200	3m	50	57	0	0	0	0	0	1	0	1	1	0	0	(0)	0	(0)
Portsmouth-A	182	T	TC500	3m	24	26	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
Edinburgh	183	T	TC500	1m	13	12	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
London-C	184	T	TC500	28d	8	10	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
Swedish	185	T	TC500	28d	21	21	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
Heidelberg-A	186	T	TC500	1m	36	33	-	-	-	-	0	0	0	0	0	0	0	(0)	1	(0)
Norfolk	187	T	S	3m	8	8	-	-	-	-	0	1	0	1	0	0	0	(0)	0	(0)
German fistula	188	P	A50 + D400	18m	451	452	-	-	-	-	21	30	21	30	2	7	-	(1)	-	(0)
Sreedhara	189	T	D225, A325, A325 + D225	18m	84	24x4		0	0	1	1	1	2	2	3	1	13	(0)	4	(0)
Grontoft	190	T	TC500	5m	144	141	0	1	0	0	5	4	5	5	0	1	5	(0)	7	(0)
STOP	191	I	PI	12m	398	413	0	0	1	7	7	11	8	18	10	8	4	(0)	4	(0)
Diabetes
Birmingham-A	192	T	TC100, TC250, TC500	2m	20	8x2	0	1	0	0	0	0	0	1	0	0	0	(0)	0	(0)
London diabetes	193	T	TC500	12m	38	40	0	0	0	1	1	1	1	2	0	0	0	(0)	0	(0)
Dutch	194	T	S	32m	30	31	1	1	1	1	2	0	4	2	0	0	0	(0)	0	(0)
DAMAD	195	T	A990, A990 + D225	36m	318	157x2	21	5	-	-	3	3	24	8	1	1	-	(0)	-	(0)
TIMAD	196	T	TC500	32m	220	215	1	3	2	2	1	2	4	7	2	2	0	(0)	0	(0)
BTRS	197	T	TC500	48m	49	51	0	1	0	0	0	0	0	1	0	0	0	(0)	0	(0)
Nyberg	198	T	TC500	12m	12	11	0	0	0	0	1	0	1	0	0	0	0	(0)	0	(0)
ETDRS	199	I	A650	60m	1856	1855	52	67	54	37	264	287	369	390	76	79	-	(-)	-	(-)
Cocozza	200	T	PI	24m	25	25	0	2	0	3	0	1	0	6	-	-	-	(-)	-	(-)
Carotid disease
Toronto	201	T	A990 + D225	7d	10	12	0	0	0	2	0	0	0	2	0	0	0	(0)	0	(0)
Bologna	202	T	TC500	8d (15d)	14	17	0	0	0	0	0	1	0	1	0	0	0	(0)	0	(0)
Vienna	203	T	A1000	54m	32	34	-	-	0	1	4	11	4	12	0	0	-	(-)	-	(-)
La Jolla	204	P	A975 + D225	12m	83	80	-	-	1	1	3	6	4	7	0	0	3	0	2	0
Pratesi	205	T	ID	6m	10	10	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)
Montreal	206	T	A325	24m	190	184	7	4	0	0	10	7	28	21	1	6	1	(-)	1	(-)

Footnotes

APT = antiplatelet; Ctrl = control. "Non-fatal stroke" includes ischaemic and haemorrhagic strokes, together with strokes of unknown aetiology. "Vascular deaths" includes deaths that were known to have a vascular cause, and deaths of unknown cause

Numbers of non-fatal major (extracranial) bleeds are shown first, with fatal bleeds in brackets then the total is shown in square brackets. If separate information on fatal and non-fatal bleeds was not available then the total is shown in square brackets. '-': data unavailable

I = individual participant data; T = tabular data checked with trialist; P = data extracted from publication(s)

A = aspirin; D = dipyridamole; S = sulfinpyrazone; H = heparin; FIB = fibrinolytic therapy; SK = streptokinase; W = warfarin; TC = ticlopidine; F = flurbiprofen; GRB = GR32191B; DZ = dazoxiben; SC = suloctidil

OKY = ozagrel; TF = triflusal; TR = trapidil; NC = nicoumalone; ST = sulotroban; ID = indobufen; OAC = oral anticoagulant; PI = picotamide; RA233 = mopidamol; doses in mg/day are shown for aspirin; dipyridamole and ticlopidine; antithrombotic or fibrinolytic drugs given as background treatment are shown in brackets

Average Duration means average scheduled treatment duration (with average duration of follow-up shown in brackets if different); m=months; d=days; h=hours

*Canadian-Cooperative patient numbers: Data unavailable for 64 patients ruled ineligible after randomisation

†MAST-I regimen: this trial had a 2 x 2 factorial design (SK vs placebo SK, A300 vs placebo). Patients randomised to SK have been excluded due to a significant interaction (with respect to absolute risk) between allocation to SK or placebo SK and the effects of aspirin

‡ALDUSA-pilot regimen: In the 40 mg arm patients were to receive 120mg on day 1 and 40mg daily thereafter

¥Florida UA: Ticlopidine was given at a dose of 750 mg daily for the first two days, and 500 mg daily thereafter

§ATACS-pilot regimen: 325 mg on day 1 and 80 mg daily thereafter

**All post-randomisation myocardial infarctions were peri-procedural, and hence occurred prior to commencing randomised treatment.